Further studies to investigate chronological changes in peripheral blood monocytic phenotypes and cytokine production in ACPA-positive and ACPA-negative RA patients treated with or without abatacept are necessary to confirm the in vivo therapeutic effects of abatacept. The gene discussed is PRTN3; the disease is rheumatoid arthritis.